Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGPS1 | O95749 | 8/20 | 0.49 |
| ▸ | FDPS | P14324 | 10/20 | 0.46 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.42 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7796960 | 0.91 | FDPS (0.55) | GGPS1FDPSLPAR3SMPD1LPAR1 | |
| SCHEMBL7549125 | 0.91 | FDPS (0.55) | GGPS1FDPSLPAR3SMPD1LPAR1 | |
| SCHEMBL4552171 | 0.87 | GGPS1 (0.48) | GGPS1FDPSLPAR3SMPD1MEN1 | |
| SCHEMBL4552690 | 0.87 | GGPS1 (0.48) | GGPS1FDPSLPAR3SMPD1MEN1 | |
| SCHEMBL1735175 | 0.79 | MAPT (0.46) | MEN1FAAHTP53CYP1A2CYP2C19 | |
| SCHEMBL7591410 | 0.79 | MAPT (0.46) | MEN1FAAHTP53CYP1A2CYP2C19 | |
| SCHEMBL16086046 | 0.79 | MAPT (0.46) | MEN1FAAHTP53CYP1A2CYP2C19 | |
| SCHEMBL5980930 | 0.79 | MAPT (0.46) | MEN1FAAHTP53CYP1A2CYP2C19 | |
| SCHEMBL7202725 | 0.79 | MAPT (0.46) | MEN1FAAHTP53CYP1A2CYP2C19 | |
| SCHEMBL4566606 | 0.77 | FDPS (0.56) | GGPS1FDPSLPAR3SMPD1LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020173489-A1 | COMPOSITIONS CONTAINING A MIXTURE OF PHOSPHOROUS COMPOUNDS AND ALKYLGLYCEROLS | MAX-PLANCK-GESSELSCHAFT ZUR FORDERUNG DER WISSENSCHAFTER E.V. (DE) | 2002-11-21 | — | — | US | disclosed |
| US-5916884-A | CYTOTOXIC THERAPEUTIC COMPOUND; ANTITUMOR AGENT | MAX-PLANCK-GESELLSCHAFT ZUR FOEDERUNG DER WISSENSCHAFTEN (DE) | 1999-06-29 | — | — | US | disclosed |
| EP-0916343-A1 | use of alkzl phosphoric acid compounds for the treatment of psoriatic diseases | ASTA Medica Aktiengesellschaft (DE) | 1999-05-19 | — | — | EP | disclosed |
| US-5290769-A | Applying compositions for skin disorders | ASTA PHARMA AKTIENGESELLSCHAFT (DE) | 1994-03-01 | — | — | US | disclosed |
| EP-0248062-B1 | MEDICAMENTS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1992-05-06 | — | — | EP | disclosed |
| EP-0419998-A2 | Use of alkylphosphonic acid derivatives for the treatment of psoriasis | ASTA Medica Aktiengesellschaft (DE) | 1991-04-03 | — | — | EP | disclosed |
| EP-0225608-A2 | Medicine | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1987-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173489-A1 | COMPOSITIONS CONTAINING A MIXTURE OF PHOSPHOROUS COMPOUNDS AND ALKYLGLYCEROLS | PHOSPHO1, PLCG2, PPIP5K2 | GGPS1 105/4885FDPS 668/4885LPAR3 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.